Reasons Bristol Myers Squibb Stock: 3 Key Arguments
Want to know if Bristol Myers Squibb is worth a spot in your portfolio? This deep dive highlights three core reasons ...
This Biopharma tag page curates 3 recent articles on biotech stocks, showing how drugmaker moves can impact prices and your portfolio. Learn why these trends matter to your finances.
8 articlesWant to know if Bristol Myers Squibb is worth a spot in your portfolio? This deep dive highlights three core reasons ...
AbbVie blew past first-quarter expectations with a $15.002 billion revenue print and raised full-year guidance, under...
A large open-market sale by Indivior's Chief Scientific Officer sparked questions about future risk and long-term val...
AbbVie’s stock has climbed since 2024, yet a stubborn balance sheet and looming biosimilar erosion create a cautious ...
Johnson & Johnson and AbbVie report strong Q1 2026 results, showcasing two contrasting growth paths as biosimilar cha...
Two pharma giants, two very different growth stories. This guide breaks down why Eli Lilly might be the best growth s...
Wall Street resorts to fresh coverage on three large cap biopharma names as Jefferies flags Gilead and Amgen while JP...
The weight loss field is heating up, with Novo Nordisk leading the GLP-1 wave and Amgen pursuing a smaller, more sele...